REFERENCES
1. Basse C, Botticella A, Molina TJ, et al. Radiorythmic: phase III, opened, randomized study of postoperative radiotherapy versus surveillance in stage IIb/III of masaoka koga thymoma after complete surgical resection. Clin Lung Cancer 2021;22:469-72.
2. Shepherd A, Riely G, Detterbeck F, et al. Thymic carcinoma management patterns among international thymic malignancy interest group (ITMIG) physicians with consensus from the thymic carcinoma working group. J Thorac Oncol 2017;12:745-51.
3. Basse C, Thureau S, Bota S, et al. Multidisciplinary tumor board decision making for postoperative radiotherapy in thymic epithelial tumors: insights from the rythmic prospective cohort. J Thorac Oncol 2017;12:1715-22.
4. Kao TN, Yang PW, Lin MW, Lee JM. Induction therapy followed by surgery for advanced thymic tumors. Asian J Surg 2020;43:707-8.
5. Conforti F, Marino M, Vitolo V, et al. Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM). ESMO Open 2021;6:100188.
6. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. ESMO guidelines committee. thymic epithelial tumours: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v40-55.
7. Imbimbo M, Ottaviano M, Vitali M, et al. Best practices for the management of thymic epithelial tumors: a position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treat Rev 2018;71:76-87.
8. Rico M, Flamarique S, Casares C, et al. GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours. World J Clin Oncol 2021;12:195-216.
9. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009;4:911-9.
10. Kumar N, Kumar R, Bera A, et al. Thymoma: clinical experience from a tertiary care institute from North India. J Cancer Res Ther 2013;9:235-9.
11. Zhang H, Lu N, Wang M, Gu X, Zhang D. Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases. Chin Med J 1999;112:136-8.
12. Gomez D, Komaki R, Yu J, Ikushima H, Bezjak A. Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thorac Oncol 2011;6:S1743-8.
13. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. J Thorac Oncol 2010;5:2017-23.
14. Rimner A, Yao X, Huang J, et al. Postoperative radiation therapy is associated with longer overall survival in completely resected stage II and III thymoma-an analysis of the international thymic malignancies interest group retrospective database. J Thorac Oncol 2016;11:1785-92.
15. Forquer JA, Rong N, Fakiris AJ, Loehrer PJ Sr, Johnstone PA. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010;76:440-5.
16. Lim YJ, Song C, Kim JS. Improved survival with postoperative radiotherapy in thymic carcinoma: a propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database. Lung Cancer 2017;108:161-7.
17. Muslim Z, Baig MZ, Weber JF, et al. Invasive thymoma - which patients benefit from post-operative radiotherapy? Asian Cardiovasc Thorac Ann 2021;29:935-42.
18. Patel S, Macdonald OK, Nagda S, Bittner N, Suntharalingam M. Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys 2012;82:1797-801.
19. Weksler B, Shende M, Nason KS, Gallagher A, Ferson PF, Pennathur A. The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study. Ann Thorac Surg 2012;93:1822-8; discussion 1828.
20. Wen J, Chen J, Chen D, et al. Evaluation of the prognostic value of surgery and postoperative radiotherapy for patients with thymic neuroendocrine tumors: a propensity-matched study based on the SEER database. Thorac Cancer 2018;9:1603-13.
21. Boothe D, Orton A, Thorpe C, Kokeny K, Hitchcock YJ. Postoperative radiotherapy in locally invasive malignancies of the thymus: patterns of care and survival. J Thorac Oncol 2016;11:2218-26.
22. Jackson MW, Palma DA, Camidge DR, et al. The impact of postoperative radiotherapy for thymoma and thymic carcinoma. J Thorac Oncol 2017;12:734-44.
23. Kim S, Bull DA, Hsu CH, Hsu CC. The role of adjuvant therapy in advanced thymic carcinoma: a national cancer database analysis. Ann Thorac Surg 2020;109:1095-103.
24. Hamaji M, Shah RM, Ali SO, Bettenhausen A, Lee HS, Burt BM. A meta-analysis of postoperative radiotherapy for thymic carcinoma. Ann Thorac Surg 2017;103:1668-75.
25. Lim YJ, Kim E, Kim HJ, et al. Survival impact of adjuvant radiation therapy in masaoka stage II to IV thymomas: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2016;94:1129-36.
26. Ma J, Sun X, Huang L, et al. Postoperative radiotherapy and tumor recurrence after complete resection of stage II/III thymic tumor: a meta-analysis of cohort studies. Onco Targets Ther 2016;9:4517-26.
27. Tateishi Y, Horita N, Namkoong H, Enomoto T, Takeda A, Kaneko T. Postoperative radiotherapy for completely resected masaoka/masaoka-koga stage II/III thymoma improves overall survival: an updated meta-analysis of 4746 patients. J Thorac Oncol 2021;16:677-85.
28. Zhou D, Deng XF, Liu QX, Zheng H, Min JX, Dai JG. The effectiveness of postoperative radiotherapy in patients with completely resected thymoma: a meta-analysis. Ann Thorac Surg 2016;101:305-10.
29. Liu Q, Gu Z, Yang F, et al. The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database. J Thorac Dis 2016;8:687-95.
30. Song SH, Suh JW, Yu WS, et al. The role of postoperative radiotherapy in stage II and III thymoma: a Korean multicenter database study. J Thorac Dis 2020;12:6680-9.
31. Bruni A, Stefani A, Perna M, et al. The role of postoperative radiotherapy for thymomas: a multicentric retrospective evaluation from three Italian centers and review of the literature. J Thorac Dis 2020;12:7518-30.
32. Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: a propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. J Thorac Cardiovasc Surg 2016;151:47-57.e1.
33. Tang EK, Chang JM, Chang CC, et al. Prognostic factor of completely resected and pathologic T3 N0 M0 thymic epithelial tumor. Ann Thorac Surg 2021;111:1164-73.
34. Tseng YH, Lin YH, Tseng YC, et al. Adjuvant therapy for thymic carcinoma-a decade of experience in a taiwan national teaching hospital. PLoS One 2016;11:e0146609.
35. Yan J, Liu Q, Moseley JN, et al. Adjuvant radiotherapy for stages II and III resected thymoma: a single-institutional experience. Am J Clin Oncol 2016;39:223-7.
36. Wang Y, Xu L, Du T, Gao Y, Wu Z, Luo D. A nomogram predicting recurrence and guiding adjuvant radiation for thymic carcinoma after resection. Ann Thorac Surg 2018;106:257-63.
37. Yun JK, Lee GD, Kim HR, et al. A nomogram for predicting recurrence after complete resection for thymic epithelial tumors based on the TNM classification: a multi-institutional retrospective analysis. J Surg Oncol 2019;119:1161-9.
38. Lee KH, Noh JM, Ahn YC, et al. Patterns of failure following postoperative radiation therapy based on “tumor bed with margin” for stage II to IV type C thymic epithelial tumor. Int J Radiat Oncol Biol Phys 2018;102:1505-13.
39. Wang CL, Gao LT, Lyu CX, et al. Intensity modulated radiation therapy for pleural recurrence of thymoma: a prospective phase 2 study. Int J Radiat Oncol Biol Phys 2021;109:775-82.
40. Yang AJ, Choi SH, Byun HK, Kim HJ, Lee CG, Cho J. The role of salvage radiotherapy in recurrent thymoma. Radiat Oncol J 2019;37:193-200.
41. Hao XJ, Peng B, Zhou Z, Yang XQ. Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment. Sci Rep 2017;7:13549.
42. Barsky AR, Yegya-Raman N, Katz SI, Simone CB 2nd, Cengel KA. Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy. Lung Cancer 2021;157:163-4.
43. Kashima J, Okuma Y. New histological classification and staging of thymic malignancies: ITMIG consensus statements and the 8th TNM staging system. J Thorac Dis 2017;9:3656-8.
44. Kim YJ, Kim SS, Song SY, et al. Elective nodal irradiation as adjuvant radiotherapy for advanced thymomas and thymic carcinomas. Clin Lung Cancer 2019;20:e91-6.
45. Chevli N, Bland RE, Farach AM, et al. Adaptive radiation therapy for intact thymoma: an illustrative report. Anticancer Res 2021;41:2467-71.
46. Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol 2010;5:S336-43.
47. Mercado CE, Hartsell WF, Simone CB 2nd, et al. Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. Acta Oncol 2019;58:1036-40.
48. Vogel J, Berman AT, Lin L, et al. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: early response and toxicity assessment. Radiother Oncol 2016;118:504-9.
49. Vogel J, Lin L, Litzky LA, Berman AT, Simone CB 2nd. Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma. Int J Radiat Oncol Biol Phys 2017;99:427-33.
50. Vogel J, Lin L, Simone CB 2nd, Berman AT. Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies. Acta Oncol 2017;56:1060-4.
51. Haefner MF, Verma V, Bougatf N, et al. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta Oncol 2018;57:1713-20.
52. Molitoris JK, Diwanji T, Snider JW 3rd, et al. Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer. J Thorac Dis 2018;10:S2437-50.
